This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB571 in participants with gastrointestinal tumors.
Male or female, age ≥ 18 years and ≤ 75 years at the time of signing the informed consent form (ICF).
Participants must have histologically or cytologically confirmed gastrointestinal tumors.
At least one measurable lesion as assessed by the investigator according to RECIST v1.1.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Participants with other malignant tumors within 3 years before the first dose of study treatment.
History or current metastases to central nervous system.
Current uncontrolled concomitant diseases
Clinically severe lung damage due to complications of lung disorder